Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis

摘要: Objective To assess the efficacy and cost-effectiveness of modulated electrohyperthermia (mEHT) concurrent to dose-dense temozolomide (ddTMZ) 21/28 days regimen versus ddTMZ alone in patients with recurrent glioblastoma (GBM). Design A cohort 54 GBM treated ddTMZ+mEHT 2000–2005 was systematically retrospectively compared five pooled cohorts (114 patients) enrolled 2008–2013. Results The ddTMZ+mEHT cohort had a not significantly improved mean survival time (mST) comparator (p=0.531) after less number cycles (1.56 vs 3.98, p Conclusions Our ETA suggests that mEHT improves receiving regimen. Economic evaluation is cost-effective, budget-saving profitable. After confirmation results, could be recommended for treatment as cost-effective enhancer regimens, and, probably, regular 5/28 applicable also single if chemotherapy impossible, salvage failure chemotherapy.